Cheema Tooba A, Pettigrew Veryan A, Fisher Stephen K
Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI 48109-0220, USA.
J Pharmacol Exp Ther. 2007 Mar;320(3):1068-77. doi: 10.1124/jpet.106.115741. Epub 2006 Dec 5.
The basal (swelling-induced) and receptor-stimulated effluxes of (125)I(-) and taurine have been monitored to determine whether these two osmolytes are released from human SH-SY5Y cells under hypotonic conditions via common or distinct mechanisms. Under basal conditions, both (125)I(-) (used as a tracer for Cl(-)) and taurine were released from the cells in a volume-dependent manner. The addition of thrombin, mediated via the proteinase-activated receptor-1 (PAR-1) subtype, significantly enhanced the release of both (125)I(-) and taurine (3-6-fold) and also increased the threshold osmolarity for efflux of these osmolytes ("set-point") from 200 to 290 mOsM. Inclusion of a variety of broad-spectrum anion channel blockers and of 4-[(2-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy]butanoic acid attenuated the release of both (125)I(-) and taurine under basal and receptor-stimulated conditions. Basal release of (125)I(-) and taurine was independent of Ca(2+) or the activity of protein kinase C (PKC). However, although PAR-1-stimulated taurine efflux was attenuated by either a depletion of intracellular Ca(2+) or inhibition of PKC by chelerythrine, the enhanced release of (125)I(-) was independent of both parameters. Stimulated efflux of (125)I(-) after activation of muscarinic cholinergic receptors was also markedly less dependent on Ca(2+) availability and PKC activity than that observed for taurine release. These results indicate that, although the osmosensitive release of these two osmolytes from SH-SY5Y cells may occur via pharmacologically similar membrane channels, the receptor-mediated release of (125)I(-) and taurine is differentially regulated by PKC activity and Ca(2+) availability.
已监测了(125)I⁻和牛磺酸的基础(肿胀诱导)流出以及受体刺激流出,以确定这两种渗透溶质在低渗条件下是否通过共同或不同机制从人SH - SY5Y细胞中释放。在基础条件下,(125)I⁻(用作Cl⁻的示踪剂)和牛磺酸均以体积依赖性方式从细胞中释放。通过蛋白酶激活受体-1(PAR-1)亚型介导添加凝血酶,显著增强了(125)I⁻和牛磺酸的释放(3至6倍),并且还将这些渗透溶质流出的阈值渗透压(“设定点”)从200 mOsM提高到290 mOsM。加入多种广谱阴离子通道阻滞剂和4-[(2-丁基-6,7-二氯-2-环戊基-2,3-二氢-1-氧代-1H-茚-5-基)氧基]丁酸可减弱基础和受体刺激条件下(125)I⁻和牛磺酸的释放。(125)I⁻和牛磺酸的基础释放与Ca²⁺或蛋白激酶C(PKC)的活性无关。然而,尽管PAR-1刺激的牛磺酸流出可通过细胞内Ca²⁺耗竭或白屈菜红碱抑制PKC而减弱,但(125)I⁻的增强释放与这两个参数均无关。毒蕈碱型胆碱能受体激活后(125)I⁻的刺激流出也比牛磺酸释放观察到的情况明显更少依赖于Ca²⁺可用性和PKC活性。这些结果表明,尽管这两种渗透溶质从SH - SY5Y细胞的渗透敏感性释放可能通过药理学上相似的膜通道发生,但(125)I⁻和牛磺酸的受体介导释放受PKC活性和Ca²⁺可用性的差异调节。